Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bjørn, M.E., de Stricker, K., Kjær, L., Ellemann, K., Hasselbalch, H.C.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2014
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4216335/
https://ncbi.nlm.nih.gov/pubmed/25379406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2014.05.003
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares